Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

This study is testing a combination of two drugs — zanubrutinib (a targeted oral therapy) and rituximab (an antibody that targets cancer cells) — as the first treatment for people with marginal zone lymphoma, a type of slow-growing blood cancer. **You may be eligible if...** - You have been diagnosed with CD20-positive marginal zone lymphoma confirmed by biopsy - You have not previously received any treatment for this cancer - You have at least one measurable tumor (lymph node larger than 1.5 cm, or other lesion larger than 1 cm) - You have agreed to participate and signed the consent form **You may NOT be eligible if...** - You have another active or prior cancer that requires treatment - You are receiving any other anti-cancer drugs alongside this study treatment - You have not had your diagnosis confirmed by tissue biopsy - You are unable to complete follow-up visits Talk to your doctor to see if this trial is right for you.